Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 33, Issue 6, 2013, Pages 845-851

  Liang, Yi Chen ^a   Wu, Hong Ge ^a   Xue, Hong Jian ^a   Liu, Qing ^a   Shi, Liang Liang ^a   Liu, Tao ^a   Wu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

acquired gefitinib resistance; lung adenocarcinoma H1975 cell line; NVP BKM120

Indexed keywords

AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BUPARLISIB; GEFITINIB; GELATINASE B; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MMP9 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; NVP-BKM120; PHOSPHATIDYLINOSITOL 3 KINASE; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; QUINAZOLINES; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891595627     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-013-1209-5     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010,60(5):277-300
2. Jeremic B, Milicic B, Dagovic A, et al. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol, 2003,129(2): 114-122 (Pubitemid 36470093)
3. Wakelee HA, Bernardo P, Johnson DH, et al. Changes in the natural history of nonsmall cell lung cancer (NSCLC)-comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer, 2006,106(10):2208-2217 (Pubitemid 43673243)
4. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008,83(5):584-594 (Pubitemid 351720831)
5. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: updated 2003. J Clin Oncol, 2004,22(2):330-353 (Pubitemid 41095099)
6. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000,18(10):2095-2103 (Pubitemid 30324363)
7. Idbaih A, Aimard J, Boisselier B, et al. Epidermal growth factor receptor mutations in lung cancer. J Neuropathol Appl Neurobiol, 2009,35(2):208-213
8. Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist, 2006,11(4): 358-373
9. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007,7(3):169-181
10. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004,304(5676):1497-1500 (Pubitemid 38720929)
11. Costa DB, Kobayashi S, Tenen DG, et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer, 2007,58(1):95-103 (Pubitemid 47379970)
12. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med, 2005,352(8):786-792 (Pubitemid 40271173)
13. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2005,2(3):e73 (Pubitemid 40629469)
14. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA, 2008,105(6):2070-2075 (Pubitemid 351439466)
15. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007,316(5827): 1039-1043 (Pubitemid 46799492)
16. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA, 2007,104(52): 20932-20937
17. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med, 2010,2(51):51-70
18. Aziz SA, Jilaveanu LB, Zito C, et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res, 2010,16(24): 6029-6039
19. Gendreau SB, Ventura R, Keast P, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res, 2007,13(12): 3713-3723 (Pubitemid 46955136)
20. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer, 2008,99(6): 911-922
21. Rho JK, Choi YJ, Ryoo BY, et al. P53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res, 2007,67(3):1163-1169
22. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc, 2008,3(6): 1101-1108 (Pubitemid 351818697)
23. Wang L, Zhang Q, Zhang J, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 2011,11:248
24. Nicholson KM, Anderson NG. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal, 2002,14(5):381-395 (Pubitemid 34214843)
25. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet, 2006,7(8):606-619 (Pubitemid 44100518)
26. Aziz SA, Davies M, Pick E, et al. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res, 2009,15(9):3029-3036
27. Martin KA, Blenis J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res, 2002,86:1-39
28. Richardson CJ, Schalm SS, Blenis J. PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol, 2004,15 (2):147-159 (Pubitemid 38251643)
29. Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer, 2009,124(8):1778-1784
30. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA, 2001,98(20):10 983-10 985 (Pubitemid 32928669)
31. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta, 2004,1697(1-2):3-16 (Pubitemid 38326757)
32. Gao N, Nester RA, Sarkar MA. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/ Akt/FRAP pathway in OVCAR-3 and A27802CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol, 2004,196(1):124-135 (Pubitemid 38393700)
33. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 2001,21(12):3995-4004 (Pubitemid 32476461)